Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).
In this manuscript, we describe our ongoing randomized clinical trial to assess the efficacy of blood pressure control with angiotensin converting enzyme (ACE) inhibition on renal cyst growth over a 5-year study period in children and young adults aged 4-21 years with autosomal dominant polycystic kidney disease (ADPKD). Baseline demographic and laboratory data for the study groups are reported. Results of this study could significantly impact the standard of care for management of ADPKD in this population.
Cadnapaphornchai
Melissa A
MA
Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado, USA.
Fick-Brosnahan
Godela M
GM
Duley
Irene
I
Johnson
Ann M
AM
Strain
John D
JD
DeGroff
Curt G
CG
Schrier
Robert W
RW
D000293:Adolescent; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D018579:Patient Selection; D016891:Polycystic Kidney, Autosomal Dominant / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D012107:Research Design; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril